@article{5ae53c7bd9a847fe8c3f947d37fc3740,
title = "Clopidogrel and coronary stents: Risks and benefits",
abstract = "Clopidogrel has become increasingly important in the management of patients with coronary stents. Clopidogrel is an oral agent that acts on the adenosine diphosphate receptor to irreversibly inhibit platelet aggregation. Along with aspirin, clopidogrel has a significant role in the treatment of atherothrombotic diseases. Recent concerns about late stent thrombosis highlight the need for long-term therapy with clopidogrel in addition to aspirin in these populations. This article reviews the role of clopidogrel in the treatment of atherothrombotic diseases and after coronary intervention, as well as the current approach in the prevention of stent thrombosis. It also discusses experimental and upcoming drugs that may be superior to clopidogrel.",
author = "Mood, {Girish R.} and Bavry, {Anthony A.} and Bhatt, {Deepak L.}",
note = "Funding Information: Dr. Bhatt has received research grants (directly to the institution) from Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi-Aventis, and The Medicines Company. He has received honoraria (donated to nonprofits for > 2 years) from Astra Zeneca, Bristol-Myers Squibb, Centocor, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Millennium, Paringenix, PDL, Sanofi-Aventis, Schering-Plough, The Medicines Company, and tns Healthcare. He has been on the speaker{\textquoteright}s bureau (> 2 years ago) of Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company and has served on the Consultant/Advisory Board (donated to nonprofits for > 2 years) of Astellas, AstraZeneca, Bristol-Myers Squibb, Cardax, Centocor, Cogentus, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, McNeil, Medtronic, Millennium, Molecular Insights, Otsuka, Paringenix, PDL, Philips, Portola, Sanofi-Aventis, Schering-Plough, Scios, Takeda, The Medicines Company, tns Healthcare, and Vertex. He has given expert testimony regarding clopidogrel (> 2 years ago; the compensation was donated to a nonprofit organization). The Cleveland Clinic Coordinating Center currently receives or has received research funding from Abraxis, Alex-ion Pharma, AstraZeneca, Atherogenics, Aventis, Biosense Webster, Biosite, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardionet, Centocor, Converge Medical Inc., Cordis, Dr. Reddy{\textquoteright}s, Edwards Lifesciences, Esperion, GE Medical, Genentech, Gilford, GSK, Guidant, J&J, Kensey-Nash, Lilly, Medtronic, Merck, Mytogen, Novartis, Novo Nordisk, Orphan Therapeutics, P&G Pharma, Pfizer, Roche, Sankyo, Sanofi-Aventis, Schering-Plough, Scios, St. Jude Medical, Takeda, TMC, VasoGenix, and Viacor.",
year = "2008",
doi = "10.1007/s11883-008-0047-6",
language = "English (US)",
volume = "10",
pages = "303--308",
journal = "Current atherosclerosis reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "4",
}